SAN FRANCISCO – Although most of the biotech world was starting last week with a J.P. Morgan Healthcare Conference hangover, it was business as usual for the redoubtable Steve Burrill, whose life sciences venture firm, Burrill & Co., recently added Capital Fund IV to its portfolio.
SAN FRANCISCO – Although most of the biotech world is starting the week with a J.P. Morgan Healthcare Conference hangover, it's business as usual for the redoubtable Steve Burrill, whose life sciences venture firm, Burrill & Co., recently added Capital Fund IV to its portfolio.
Privately held Nuron Biotech Inc. hooked a big fish for its first licensing deal. The Exton, Pa.-based company signed an agreement with Mitsubishi Tanabe Pharma Corp. (MTPC), of Osaka, Japan, to commercialize its HibTiter vaccine (Haemophilus b conjugate vaccine [diphtheria CRM197 protein conjugate]) in Japan, both as a single entity and for combination product use.
SAN FRANCISCO – Regenerative medicine is coming of age, and not a day too soon to address an expected 80 percent increase in individuals older than 65 expected by 2030, from 40 million to more than 70 million in the U.S. alone.
SAN FRANCISCO – The nexus of clinical development, regulation and capital was the focus of a panel convened Tuesday at the 30th annual J.P. Morgan Healthcare Conference to discuss a biomedical industry CEO survey conducted by the nonprofit California Healthcare Initiative (CHI), the Northern California life science association BayBio and the pharmaceutical, medical device and life sciences industry group at PricewaterhouseCoopers (PwC).
SAN FRANCISCO – Heightened security in the wake of the Occupy Wall Street movement didn't deter more than 8,000 participants who flocked to San Francisco for the 30th J.P. Morgan Healthcare Conference.
Synageva BioPharma Corp. priced its underwritten public offering of common stock, seeking to raise $78.3 million by selling 3,108,057 shares at $25.18 per share.
Elevation Pharmaceuticals Inc. closed a $30 million Series B financing, led by new investor Novo Ventures, to advance its aerosol therapy for chronic obstructive pulmonary disease (COPD).
AVEO Pharmaceuticals Inc. and partner Astellas Pharma Inc. reported top-line data from the global, randomized Phase III TIVO-1 trial indicating that lead compound tivozanib demonstrated superiority over Nexavar (sorafenib, Onyx) in advanced renal cell carcinoma (RCC), meeting the primary endpoint of progression-free survival (PFS).
